ORG Partners LLC raised its stake in shares of Chemed Co. (NYSE:CHE – Free Report) by 3,475.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 429 shares of the company’s stock after purchasing an additional 417 shares during the period. ORG Partners LLC’s holdings in Chemed were worth $231,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in CHE. Rise Advisors LLC purchased a new position in shares of Chemed in the first quarter valued at about $26,000. GAMMA Investing LLC purchased a new stake in shares of Chemed in the fourth quarter worth about $37,000. Principal Securities Inc. purchased a new stake in shares of Chemed in the fourth quarter worth about $51,000. SRS Capital Advisors Inc. lifted its position in shares of Chemed by 110.6% in the fourth quarter. SRS Capital Advisors Inc. now owns 99 shares of the company’s stock worth $58,000 after buying an additional 52 shares in the last quarter. Finally, Mather Group LLC. purchased a new stake in shares of Chemed in the first quarter worth about $67,000. 95.85% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, CEO Kevin J. Mcnamara sold 1,500 shares of the stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $544.17, for a total value of $816,255.00. Following the transaction, the chief executive officer now owns 107,049 shares of the company’s stock, valued at $58,252,854.33. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Chemed news, CEO Kevin J. Mcnamara sold 1,500 shares of the stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $544.17, for a total transaction of $816,255.00. Following the sale, the chief executive officer now owns 107,049 shares of the company’s stock, valued at approximately $58,252,854.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin J. Mcnamara sold 4,000 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $567.54, for a total value of $2,270,160.00. Following the sale, the chief executive officer now directly owns 108,549 shares in the company, valued at approximately $61,605,899.46. The disclosure for this sale can be found here. Insiders have sold a total of 9,784 shares of company stock valued at $5,502,473 over the last quarter. 3.32% of the stock is owned by corporate insiders.
Chemed Price Performance
Chemed (NYSE:CHE – Get Free Report) last released its earnings results on Wednesday, July 24th. The company reported $5.47 EPS for the quarter, missing analysts’ consensus estimates of $5.59 by ($0.12). The business had revenue of $595.88 million for the quarter, compared to the consensus estimate of $599.20 million. Chemed had a net margin of 12.88% and a return on equity of 29.21%. The company’s quarterly revenue was up 7.6% compared to the same quarter last year. During the same period in the prior year, the company posted $4.71 EPS. Research analysts predict that Chemed Co. will post 21.77 earnings per share for the current year.
Chemed Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 30th. Investors of record on Monday, August 12th will be paid a $0.50 dividend. The ex-dividend date is Monday, August 12th. This represents a $2.00 annualized dividend and a yield of 0.35%. This is a boost from Chemed’s previous quarterly dividend of $0.40. Chemed’s dividend payout ratio is 10.76%.
Analysts Set New Price Targets
A number of equities research analysts recently commented on the company. Royal Bank of Canada decreased their target price on Chemed from $712.00 to $697.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 21st. StockNews.com upgraded Chemed from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th.
Get Our Latest Stock Analysis on CHE
About Chemed
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Featured Articles
- Five stocks we like better than Chemed
- What is the Euro STOXX 50 Index?
- Brinker International’s Price Dip is an Appetizing Entry Point
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 Stocks That Could Beat the September Blues
- What is an Earnings Surprise?
- Canopy Growth Stock: Can It Sustain Recent Gains?
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE – Free Report).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.